Cargando…

A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries

Traumatic brain injury (TBI) is a major health and socio-economic problem, but no pharmacological agent is currently approved for the treatment of acute TBI. Thus, there is a great need for advances in this field. Here, we describe a short peptide (sequence CAQK) identified by in vivo phage display...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, Aman P., Scodeller, Pablo, Hussain, Sazid, Joo, Jinmyoung, Kwon, Ester, Braun, Gary B., Mölder, Tarmo, She, Zhi-Gang, Kotamraju, Venkata Ramana, Ranscht, Barbara, Krajewski, Stan, Teesalu, Tambet, Bhatia, Sangeeta, Sailor, Michael J., Ruoslahti, Erkki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931241/
https://www.ncbi.nlm.nih.gov/pubmed/27351915
http://dx.doi.org/10.1038/ncomms11980
Descripción
Sumario:Traumatic brain injury (TBI) is a major health and socio-economic problem, but no pharmacological agent is currently approved for the treatment of acute TBI. Thus, there is a great need for advances in this field. Here, we describe a short peptide (sequence CAQK) identified by in vivo phage display screening in mice with acute brain injury. The CAQK peptide selectively binds to injured mouse and human brain, and systemically injected CAQK specifically homes to sites of brain injury in mouse models. The CAQK target is a proteoglycan complex upregulated in brain injuries. Coupling to CAQK increased injury site accumulation of systemically administered molecules ranging from a drug-sized molecule to nanoparticles. CAQK-coated nanoparticles containing silencing oligonucleotides provided the first evidence of gene silencing in injured brain parenchyma by systemically administered siRNA. These findings present an effective targeting strategy for the delivery of therapeutics in clinical management of acute brain injuries.